Mid-Day Market Update: Nasdaq Rises 1%; Praxis Precision Medicines Shares Plunge

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 1% on Monday.

The Dow traded up 0.73% to 33,139.03 while the NASDAQ rose 1.16% to 12,151.86. The S&P also rose, gaining, 1.05% to 4,151.62.

Also check this: Home Depot And 2 Other Stocks Insiders Are Buying


Leading and Lagging Sectors


Consumer discretionary shares jumped by 2.2% on Monday. Meanwhile, top gainers in the sector included Gaotu Techedu Inc. GOTU, up 19% and Newegg Commerce, Inc. NEGG up 18%.


In trading on Monday, energy shares fell 0.2%.


Top Headline


Science Applications International Corporation SAIC reported upbeat results for its first quarter.

Science Applications posted quarterly earnings of $1.88 per share, beating analysts’ estimates of $1.77 per share. The company’s quarterly sales came in at $2.00 billion, versus expectations of $1.93 billion.

Science Applications raised its FY23 EPS guidance from $6.80-$7.10 to $6.90-$7.20 and narrowed its FY23 sales guidance from $7.35 billion-$7.55 billion to $7.43 billion-$7.55 billion.


Equities Trading UP


DiDi Global Inc. DIDI shares shot up 47% to $2.7150 after the Chinese government said the company can resume adding new users.


Shares of Futu Holdings Limited FUTU got a boost, shooting 22% to $44.97 after the company reported Q1 earnings results.


Yumanity Therapeutics, Inc. YMTX shares were also up, gaining 34% to $1.9012 after the company announced definitive agreements for two strategic transactions. Yumanity Therapeutics agreed to sell its lead clinical-stage product candidate, YTX-7739, and discovery-stage neuroscience candidates to Janssen Pharmaceutica NV, a unit of Johnson & Johnson for $26 million. Under the second agreement, Kineta will become a wholly-owned subsidiary of Yumanity in an all-stock transaction, resulting in a combined publicly-traded company renamed Kineta Inc.


Equities Trading DOWN

Praxis Precision Medicines, Inc. PRAX shares tumbled 65% to $2.9825 after the company announced the PRAX-114 Phase 2/3 monotherapy Aria study did not achieve statistical significance on the primary endpoint.


Shares of Gevo, Inc. GEVO were down 31% to $3.15 after the company announced a $150 million registered direct offering priced at-the-market under Nasdaq rules.


Pear Therapeutics, Inc. PEAR was down, falling 19% to $3.50. Pear Therapeutics announced new analysis showing reduction in healthcare resource utilization and associated costs in patients using reSET at 6 months.


Also check out: Executives Sell Around $325M Of 3 Stocks


Commodities

In commodity news, oil traded down 0.1% to $118.81, while gold traded down 0.1% to $1,849.80.


Silver traded up 1.4% to $22.215 on Monday while copper fell 0.8% to $4.4345.



Euro zone


European shares were higher today. The eurozone’s STOXX 600 gained 1.22%, London’s FTSE 100 gained 1.38% while Spain’s IBEX 35 Index rose 1.39%. The German DAX gained 1.61%, French CAC 40 rose 1.5% and Italy’s FTSE MIB Index jumped 1.97%.

 

Economics


There were no major US economic releases Monday

Check out this: NVIDIA And 4 Other Stocks Insiders Are Selling


COVID-19 Update

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 86,522,560 cases with around 1,033,590 deaths. India confirmed a total of at least 43,181,330 cases and 524,700 deaths, while Brazil reported over 31,153,760 COVID-19 cases with 667,050 deaths. In total, there were at least 535,513,050 cases of COVID-19 worldwide with more than 6,320,680 deaths.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!